PTSD has significant genetic heritability; however, it is unclear how genetic risk influences tissue-specific gene expression. We used brain and non-brain transcriptomic imputation models to impute genetically regulated gene expression (GReX) in 9,087 PTSD-cases and 23,811 controls and identified thirteen significant GReX-PTSD associations. The results suggest 5 substantial genetic heterogeneity between civilian and military PTSD cohorts. The top studywide significant PTSD-association was with predicted downregulation of the Small Nuclear Ribonucleoprotein U11/U12 Subunit 35 (SNRNP35) in the BA9 region of the prefrontal cortex (PFC) in military cohorts. In peripheral leukocytes from 175 U.S. Marines, the observed PTSD differential gene expression correlated with the predicted blood GReX differences for these 10 individuals, and deployment stress downregulated SNRNP35 expression, primarily in Marines with post-deployment PTSD. SNRNP35 is a subunit of the minor spliceosome complex and SNRNP35 knockdown in cells validated its functional importance in U12-intron splicing. Finally, mimicking acute activation of the endogenous stress axis in mice downregulated PFC Snrnp35 expression. 15 Huckins et al. 4
SUMMARY
PTSD has significant genetic heritability; however, it is unclear how genetic risk influences tissue-specific gene expression. We used brain and non-brain transcriptomic imputation models to impute genetically regulated gene expression (GReX) in 9,087 PTSD-cases and 23,811 controls and identified thirteen significant GReX-PTSD associations. The results suggest 5 substantial genetic heterogeneity between civilian and military PTSD cohorts. The top studywide significant PTSD-association was with predicted downregulation of the Small Nuclear Ribonucleoprotein U11/U12 Subunit 35 (SNRNP35) in the BA9 region of the prefrontal cortex (PFC) in military cohorts. In peripheral leukocytes from 175 U.S. Marines, the observed PTSD differential gene expression correlated with the predicted blood GReX differences for these 10 individuals, and deployment stress downregulated SNRNP35 expression, primarily in Marines with post-deployment PTSD. SNRNP35 is a subunit of the minor spliceosome complex and SNRNP35 knockdown in cells validated its functional importance in U12-intron splicing. Finally, mimicking acute activation of the endogenous stress axis in mice downregulated PFC Snrnp35 expression.
INTRODUCTION
Trauma exposure is ubiquitous, particularly in veterans and impoverished, high-risk civilian populations. Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition, occurring in some individuals exposed to trauma, while the large proportion of individuals do not experience PTSD, and remain resilient even after repeated, prolonged or severe exposure to 5 trauma (Bonanno, 2004; Kessler et al., 2005; Kessler et al., 1995) . Understanding which individuals may be susceptible or resilient to PTSD is vital in the development of effective interventions and treatments. Twin studies have repeatedly demonstrated that PTSD diagnosis and symptoms are heritable, with heritability estimates ranging from 30-71% (Daskalakis et al., 2018b; Nievergelt et al., 2018a) , in line with other psychiatric disorders. Several genome-wide 10 association studies (GWAS) have identified genetic variants or loci associated with PTSD susceptibility, although most of the associations have failed to replicate (Daskalakis et al., 2018b; Nievergelt et al., 2018a) . Most recently, a GWAS by the Psychiatric Genomics Consortium for PTSD (PGC-PTSD) demonstrated SNP-based heritability of 21%, comparable to other psychiatric disorders, and demonstrated genetic correlations with schizophrenia, bipolar disorder, 15 and major depressive disorder (Duncan et al., 2018 ).
Despite the substantial success of GWAS in elucidating the genetic etiology of psychiatric disorders, resulting associations may be difficult to interpret biologically. At best, these studies result in large lists of associated loci, which require careful curation to prioritize genes (Visscher 20 et al., 2017) . On the other hand, studies of the transcriptome may yield more readily biologically interpretable results. However, progress in these studies in hampered by small sample sizes, due in part to the cost and inaccessibility of the primary tissue of interest, i.e. brain. Transcriptomic Imputation (TI) approaches leverage large reference transcriptome data sets, e.g. the Genotype-Tissue Expression (GTEx) project and CommonMind Consortium (CMC) , in order to estimate 25 relationships between genotypes and gene expression, and to create predictor models of genetically regulated gene expression (GReX) (Gamazon et al., 2015; Gusev et al., 2016) . TI algorithms, thus, allow us to identify genes with predicted disease-associated differential GReX in specific tissue. These analyses allow us to probe gene expression in vastly larger sample sizes, yielding sufficient power to detect genes with small effect sizes (Gamazon et al., 2015) , which 30 represent a substantial proportion of the risk for complex diseases (Fromer et al., 2016) .
Notably, PTSD development and symptom trajectories differ according to trauma type. For example, the prevalence of PTSD differs significantly between rape survivors (45%), combat veterans (30%) and following natural disasters (4%) (Kessler et al., 2017; Kessler et al., 2005; Yehuda et al., 2015) . Both in civilian and military populations, index trauma type and exposure 5 severity significantly predict PTSD diagnosis, symptom severity, and severity of severity of specific symptom clusters (Graham et al., 2017; Jakob et al., 2017; Kessler et al., 2005; Prescott, 2012 ). While the differential prevalence, symptoms, and outcomes have been characterized in depth, to our knowledge no study has investigated differing genetic underpinnings of PTSD according to trauma type. The current PGC-PTSD study includes large collections of both 10 military PTSD (M-PTSD) and civilian PTSD (C-PTSD) cohorts. Although these are only a proxy for trauma type (e.g., combat veterans can experience non-combat military trauma and trauma in their civilian life, and both military and civilian trauma cohorts include a wide range of trauma types) and a number of individual factors in addition to trauma type may differentiate these cohorts, they provide a powerful opportunity to begin to probe differing genetic etiologies of 15 PTSD between these two groups.
RESULTS
Genetically regulated gene expression in brain and non-brain tissues is associated with PTSD 20 We imputed GReX across 32,898 individuals (9,087 cases and 23,811 controls; demographics in Table S1A ; analytic plan in Figure S1 ) from the largest multi-cohort PTSD GWAS, collected by PGC-PTSD and tested for association with case-control status. Since PTSD development involves multi-systemic dysregulation (Daskalakis et al., 2018a; Sareen, 2014) , we imputed GReX in 22 tissues, using GTEx-and CMC-derived predictor models (11 brain regions, five 25 cardiovascular tissues, three endocrine tissues, one peripheral nerve, subcutaneous adipose tissue and whole blood).
No genes reached study-wide significance (p=2.36x10 -7 ; based on 211,466 tissue-gene pairs, across all tissues) in our overall trans-ethnic meta-analysis (Manhattan plot in Figure 1A ; 30 association statistics and gene names in Table 1) , including African American (AA), European American (EA), Latino or Hispanic American (LA) and South African (SA) cohorts as in (Duncan et al., 2018) . However, DLG4 (Pituitary, p=4.51x10 -7 ), encoding for postsynaptic density protein 95 (PSD-95), and SNRNP35 (Prefrontal cortex (PFC) BA9, p=4.25x10 -6 ), encoding for Small Nuclear Ribonucleoprotein U11/U12 Subunit 35, reached within-tissue significance (5.24x10 -6 based on an average of 9542 genes in each tissue; exact statistical 5 thresholds in Table S2 ). In our EA-specific meta-analysis (5,236 cases and 13,357 controls) , SNRNP35 reached study-wide significance (PFC BA9, p=5.47 x10 -08 ).
GReX associations differ between Military and Civilian PTSD cohorts
We next hypothesized that the genetic architecture of PTSD may differ according to trauma type. 10 The genetic signatures underlying predisposition to PTSD following combat or other militaryspecific trauma may be distinct from those underlying PTSD following motor vehicle accident, neighborhood or domestic violence and sexual assault. We therefore stratified our meta-analysis according to trauma type, using military and civilian cohorts as proxies. Our M-PTSD metaanalysis, comprised of 6,109 cases and 13,850 controls, identified two genes reaching study-wide 15 significance; SNRNP35 (PFC BA9, p=8.85x10 -8 ) and SENP1 (Atrial Appendage, p=2.08x10 -7 ), both on chromosome 12 ( Figure 1B) . A third gene reached within-tissue significance; NEDD9 (Anterior Cingulate Cortex BA24, p=3.18x10 -6 ). When restricting our analysis to only military cohorts of EA descent, the SNRNP35 association remained study-wide significant, while the SENP1 association reached only within-tissue significance in the same analysis (Table 1) . A 20 third gene, RPS3, reached within-tissue significance in this EA analysis, as did two further genes, SYNGR2 and CNOT1, in the AA analysis. We did not identify any genes reaching study-wide significance in our C-PTSD transethnic analysis (2,978 cases and 9,961 controls; Figure 1C ), which may be, in part, due to its lower 25 power and smaller sample size compared to the respective military analysis. Two genes (GCM1 and MARCH11) reached within-tissue significance in EA-and AA-specific C-PTSD analysis, respectively ( Table 1) . Notably, the genes reaching study-wide significance in our military analysis do not approach significance in our civilian analysis; rather, as demonstrated in Figure1B-C, these associations seem to be trauma type specific. 30 
Trauma-type specific associations are not driven by gender differences
It is possible that these proxy trauma types, and the resulting different association patterns, are confounded by sex. Notably, the M-PTSD sample is primarily male (~90%). We hypothesized that, if these association patterns are indeed driven by sex, we should see an enrichment of shared nominally-significant associations and greater correlation of association statistics within-5 sex compared to within trauma type.
To test this hypothesis, we compared four analyses: male C-PTSD, female C-PTSD, male M-PTSD, and female M-PTSD, for all 22 tissues. We saw significant enrichment of nominally significant male C-PTSD associations in female C-PTSD, and vice-versa (binomial tests P-value 10 < 5.9x10 -8 ), but not in any of the other pairwise enrichments (Table S3A ). Further, (Table S3B) , male C-PTSD and male M-PTSD association statistics were uncorrelated (average across-tissue Pearson correlation and P-value: r=0.001, p=0.457), while male C-PTSD and female C-PTSD association statistics had a significant relationship (r=0.138, p=4.4x10 -42 ). Despite this broad lack of support for the hypothesis of sex differences driving the trauma type specific signals, we note 15 that our top M-PTSD association, SNRNP35, reached study-wide significance in male-specific meta-analyses: of EA cohorts (Table S4 ; 3512 cases/ 11769 controls) and of EA M-PTSD cohorts (3367 cases/ 10754 controls), but not in any of our female analyses, implying that this association may have trauma type, ancestry and sex specificity. Our male-specific meta-analyses also identified additional three genes (including SENP1) reaching tissue-specific significance, 20 and the female-specific analyses identified two other genes (Table S4 ). However, none of these genes were significant in both the male and female meta-analyses, and, given the small sample sizes of some of our meta-analyses, especially male C-PTSD and female M-PTSD (Table S1B) , we urge that sex-specific analyses be pursued further in larger datasets. 25 
GReX associations with PTSD are enriched for known and novel pathways
We used MAGMA (de Leeuw et al., 2015) to test for gene-set enrichment in our overall, C-PTSD and M-PTSD transethnic meta-analyses' results. For each analysis, we tested for enrichment of a set of PTSD candidate genes identified in previous PTSD literature (Table S5) , 92 hypothesis-driven gene-sets and ~8,500 publicly available gene-sets (Supplementary 30 Materials). First, our literature-derived PTSD candidate genes were significantly enriched in the C-PTSD analysis (Table S6 ; p=0.0014), but not the overall, or M-PTSD analyses. The top individual genes included RIN1 (p=1.94 x10 -4 ), GJA1 (p=2.52 x10 -4 ), BDNF (p=3.90 x10 -4 ), OXTR (p=4.24 x10 -4 ) and DNMT1 (p=8.71 x10 -4 ); none with within-tissue significance.
We identified two gene-sets that were significantly enriched in the overall analysis (Table S6) : 5 protein phosphatase type 2A regulator activity (p=2.26x10 -6 ) and uric acid levels (p=9.94 x10 -5 ).
We then identified 11 significantly enriched gene-sets (with FDR<0.1) in the C-PTSD analysis (Table S6) , including, from our hypothesis-driven analysis: genes intolerant to loss-of-function mutations (p=9.98x10 -5 ), PSD-95 gene-set (p=0.0053), genes with loss-of-function mutations in autism (p=0.0058) and two circadian rhythm pathways (p<0.0063). Our agnostic analysis 10 identified further gene-sets related to head shortening and head dysmorphology in mice (p<1.98x10 -5 ), and early phase of HIV Life Cycle (p=2.22 x10 -5 ).
Finally, we identified 29 gene-sets significantly enriched in the M-PTSD analysis ( Table S6 ).
Only one gene-set from the hypothesis-driven analysis was significant; H3K27 acetylation peaks 15 specific to dorsolateral PFC (DLPFC) neurons (p= 6.4x10 -4 ). 28 gene-sets from our agnostic analysis were significant; these included astrocyte differentiation (p= 1.51x10 -7 ), two olfactory pathways (p< 5.55x10 -7 ), multiple pathways associated with glia functions (p< 5.14x10 -5 ), decreased motor neuron number (p= 1.94x10 -5 ), two pathways related to protein tyrosine kinase activity (p< 5.15x10 -5 ) and two pathways related to RNA stability (p< 1.15x10 -4 ). 20 
Predicted PTSD GReX differences are concordant with the observed PTSD gene expression differences
We sought to validate our GReX results in a subset of our PGC-PTSD samples for which observed peripheral leukocyte gene expression data was generated as part of a large prospective 25 U.S. Marine cohort, the Marine Resiliency Study (MRS; Supplementary Materials, Figure S2 ).
Clinical interviews and peripheral blood samples were collected from U.S. Marines one month prior-to deployment (i.e. pre-deployment, N=175) and three-months following exposure to conflict zones (i.e. post-deployment, N=157). We performed, at both time points, a differential expression analysis based on post-deployment PTSD, covarying for genetic ancestry, age, 30 traumatic brain injury (TBI), alcohol and nicotine. We identified 280 genes nominally associated with future development of PTSD at pre-deployment, and 160 genes at post-deployment (p <0.05; Table S7 ).
In parallel, we carried out differential expression analysis on all GReX imputed tissues, and on all paired samples for which observed blood gene expression was available using a matching 5 strategy (Tables S8A-B ). We then examined the association between directionality of change statistics (log fold-change) for the observed differential expression and predicted differential GReX. The correlations between observed and whole blood GReX fold-changes were significant at both pre-(r=0. 45, p=1.39×10 -7 , Figure 2A , Table S9 ) and post-deployment (r=0.47, p=3.09×10 -8 , Figure 2B , Table S9 ). We also found the strongest concordance of observed PTSD 10 effects with predicted effects on whole-blood GReX, compared to GReX of all other tissues, validating not only the accuracy and tissue-specificity of our TI-based approach (Figure 2C-D; Table S9 ). 15 The longitudinal design of the MRS enabled us to compare baseline to post-deployment peripheral leukocyte gene expression, separately for PTSD cases and control samples. We identified 1335 genes with FDR-significant longitudinal changes in expression in PTSD cases and 1161 genes in control samples (Table S10) . SNRNP35, which was the gene with the most significant GReX associations with M-PTSD (Table 1) , was found to be downregulated in 20 response to deployment stress more strongly in PTSD cases than in control samples (FC= -0.137, p=0.0025 - Figure 2E ; FC= -0.086, p=0.02 - Figure 2F , respectively), concordant with the direction of effect in our PrediXcan analysis. 25 Our results emphasized the potential role of SNRNP35 gene expression in BA9 brain region, which together with BA46 comprise DLPFC. Co-expression network analysis of a large CMC DLPFC RNA-seq dataset (Fromer et al., 2016) of healthy subjects (N=279) revealed that SNRNP35 is part of a co-expression sub-network/module, containing 152 genes (https://www.synapse.org/#!Synapse:syn7118802). This module is enriched with a range of RNA binding 30 and processing functions (GO biological processes, molecular functions and cellular components), highlighting module functional specificity related to RNA binding (adjusted Pvalue =2.78 x10 -16 ) and RNA processing/splicing (adjusted P-value =2.01 x10 -08 ; Table S11-12).
SNRNP35 is downregulated in US Marines following deployment

SNRNP35 is part of RNA-processing gene networks in DLPFC
SNRNP35 knockdown reduces U12 splicing
SNRNP35 protein is subunit of the minor spliceosome, which catalyzes the removal/splicing of 5 an atypical class of introns -U12-type (0.5% of all introns), from messenger RNAs (mRNAs) (Turunen et al., 2013) . We tested whether SNRNP35 downregulation is sufficient to cause a functional impact on U12 splicing in cell-culture experiments. Using small hairpin RNAs (shRNAs), we specifically tested the effect of knocking down all the isoforms of SNRNP35 mRNA in HEK cells (Figure 3A-C) . This study illustrated specificity of the SNRNP35 10 knockdown, demonstrating a functional impact on U12 splicing of a target mRNA, CHD1L (Niemela et al., 2014) , but not on U2 splicing of the same mRNA (Figure 3D-E) .
SNRNP35 is downregulated in PFC by stress hormones
Given the effect of deployment stress on blood-based SNRNP35 expression in the MRS study, 15 we hypothesized that stress may also affect PFC SNRNP35 expression. Stress hormones modulate gene expression through binding to the glucocorticoid receptor (GR), and subsequent binding to glucocorticoid-binding sequences (GBS). The mouse Snrnp35 gene contains many GBS (15 sites out of a total of 196 transcription factor binding sites in the entire mouse gene; based on Gene Transcription Regulation Database (http://gtrd.biouml.org/) - Table S13 ). To 20 examine the effect of stress-related GR activation on SNRNP35 expression in a model system, we injected mice with 10 mg/kg dexamethasone (DEX), a synthetic stress hormone and potent GR-agonist. We observed significant Snrnp35 downregulation in the PFC 4 hours later (DEX (n=7 males) vs. home cage (n=6 males: adjusted P-value = 0.0303), confirming regulation of Snrnp35 by stress-hormones ( Figure 3F) . The direction of this stress-dependent effect on 25 Snrnp35 expression is consistent with the lower levels of SNRNP35 in PTSD cases identified in both our GReX analysis and the MRS study.
DISCUSSION
TI is a machine learning approach that translates GWAS findings into tissue-specific GReX 30 associations with traits, adding gene, tissue and directional resolution. Applying this method to the multi-cohort PGC-PTSD GWAS, we have discovered two new putative PTSD susceptibility genes, SNRNP35 and SENP1. Both genes are involved in post-transcriptional processes;
SNRNP35 is a subunit of the U11/12 minor spliceosome and involved in splicing of U12-type introns, and the SENP1 protein is a de-SUMOylation enzyme. SNRNP35 mRNA is predicted to be downregulated in DLPFC in PTSD, a brain region of interest as it is involved in many stress- 5 related neurobiological systems and processes (Averill et al., 2017; Nemeroff et al., 2006) .
Functional alterations in DLPFC have been described in PTSD, contributing to dysregulated circuit transmission and hypothalamus-pituitary-adrenal (HPA) axis function (Averill et al., 2017; Nemeroff et al., 2006) . SENP1 is predicted to be upregulated in the left heart muscle, fitting with substantial prevalence of cardiovascular disease in PTSD (Wolf and Schnurr, 2016) 10 and the genetic overlap with cardiometabolic traits (Sumner et al.) .
In our overall PTSD pathway analysis, we saw enrichments of only two small gene-sets (<20 genes). The first pathway is related to the activity of protein phosphatase 2A, which is an enzyme that has been shown to be increased in rat PFC and hippocampus after single or repeated 15 immobilization stress (Morinobu et al., 2003) . The second pathway is related to the levels of an antioxidant, uric acid; interestingly, antioxidant capacity has been recently studied in affective and anxiety disorders as a biomarker and treatment target (Black et al., 2018) . The C-PTSD pathway analysis revealed an enrichment for genes derived from the PTSD literature. Furthermore, the enrichment of genes associated with circadian rhythms was expected given the 20 wealth of PTSD research in this area, and the common presentation of PTSD with sleep dysfunction, including insomnia and nightmares. To name a few, studies revealed altered circadian rhythms of cortisol in individuals with PTSD (Yehuda et al., 1996) , and association between PTSD and variants in circadian rhythm genes (Linnstaedt et al., 2018; Logue et al., 2013) . Finally, the enrichment of the PSD-95 gene set aligns with substantial evidence 25 supporting a role for PSD-95 in synapse-related dysfunction in several neuropsychiatric disorders (Penzes et al., 2011) . The gene encoding PSD-95 is highly expressed in the brain (incl. pituitary; (GTEx Consortium, 2017) ) and was also the top-gene in our overall PTSD metaanalysis.
A number of the M-PTSD specific functional enrichments are also highly plausible; for example, enrichment H3K27 acetylation peaks from a gene-set derived from DLPFC neurons (Girdhar et al., 2018) , known to have a role in stress models and neuropsychiatric disorders (McEwen et al., 2015) , including PTSD (Maddox et al., 2018) . Our results highlight a potential shared genetic basis between olfaction and M-PTSD, in line with previous findings of differential olfactory 5 identification in individuals with combat-related M-PTSD compared to healthy controls (Vasterling et al., 2000) ; olfactory triggers for PTSD intrusion symptoms (Daniels and Vermetten, 2016) ; olfactory-based treatments for PTSD (Aiken and Berry, 2015) ; and the key role of olfaction in fear conditioning in animal models (Morrison et al., 2015) . Given the significant genetic overlap between olfaction and PTSD, our results support the hypothesis that 10 differential sensitivity to odors may predispose to development of PTSD. Finally, the enrichment of gliogenesis, and glial and astrocyte differentiation in PTSD genetic susceptibility, is in concordance with the wealth of recent literature involving both these non-neuronal cell types with stress-related pathophysiology (Hodes et al., 2015; Sanacora and Banasr, 2013) . 15 Both genes reaching study-wide significance (SNRNP35, SENP1) were significant in the M-PTSD, but not C-PTSD, analysis. Before interpreting M-PTSD and C-PTSD differences in genetic architecture, it is important to recognize a few methodological or statistical limitations. It is likely that the proxies used to delineate trauma type are imperfect, as inclusion of an individual in a military cohort does not preclude an experience of civilian trauma. These delineations also 20 lacked nuance; for example, we do not distinguish between different types of military and civilian trauma or differences in the degree of trauma exposure. Civilian trauma is associated with more etiologic heterogeneity (clinical presentation differences among exposed individuals), while military trauma is related to more clinical heterogeneity (clinical presentation differences among those meeting PTSD diagnosis) (Prescott, 2012) . Moreover, military cohorts may be 25 more homogeneous in terms of gender (predominantly male), ancestry (mostly EA), and age than the civilian, and the lack of significance for these two genes in the transethnic or ancestryspecific C-PTSD analyses may be attributable to lack of power. We also note that there may be differences in control ascertainment between the two groups; whereas controls for military cohorts are trauma-exposed service members without PTSD, controls within civilian cohorts may 30 be more diverse in the degrees of exposure trauma. Therefore, combining all civilian trauma studies may reduce the likelihood of identifying genes for C-PTSD-risk Finally, our C-PTSD analysis was based on raw genotype (Gamazon et al., 2015) , while M-PTSD analysis was based on summary statistics (Barbeira et al., 2018) . However, it is unlikely that these factors account entirely for the difference in effect sizes between C-PTSD and M-PTSD. 5 Sex differences in trauma exposure, symptom expression, levels of support, access to treatment, and treatment response may substantially affect PTSD outcomes (Breslau, 2002; Olff, 2017) .
The latest PGC-PTSD GWAS study has shown evidence for different SNP-heritability between men and women (Duncan et al., 2018) . In the present study, we were able to investigate the contributions of sex to the genetic associations with PTSD in the military and civilian cohorts. 10 Our comparisons of male-specific and female-specific C-PTSD and M-PTSD signals did not indicate any higher similarity between male-specific M-PTSD and male-specific C-PTSD compared to the similarity between male-specific M-PTSD and female-specific M-PTSD or male-specific C-PTSD and female-specific C-PTSD. Thus, the M-PTSD findings appear to be at least partially trauma type specific, rather than driven by sex. We urge that these questions be 15 addressed in future large-scale PTSD GWAS; our analysis is relatively small, particularly with regards to military females, and we did not have access to raw genotype data for the military cohorts, precluding a more nuanced sex-specific analysis.
The M-PTSD and C-PTSD differences are intriguing and suggest that further research is 20 necessary to elucidate the potentially different genetic etiologies of PTSD related to civilian and military trauma. To date, C-PTSD and M-PTSD have been considered the same disease, with comparable biological underpinnings. However, C-PTSD and M-PTSD sometimes differ in terms of clinical presentation, prevalence and environmental risk factors; for example, trauma severity, gender, age, race all have significantly different effect sizes between C-PTSD and M- 25 PTSD. Little is known about the possible biological and molecular differences between C-PTSD and M-PTSD. Not surprisingly, biomarkers discovered in civilian studies are not always replicated in military studies (D. Norrholm and Jovanovic, 2011) . For instance, genetic risk factors discovered in the largest PTSD-GWAS meta-analysis, which consisted of 82% civilian trauma samples, were not replicated in a large military sample, and vice versa (Duncan et al., 30 2018; Stein et al., 2016) . Based on our results and previous findings, we hypothesize that C-PTSD and M-PTSD may have both shared and distinct genetic etiology, in line with subtypes of other complex, heterogeneous psychiatric disorders (Charney et al., 2017) , or pairs of psychiatric disorders with substantial etiologic, symptomatic and diagnostic overlap ( Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2018) . For these types of studies, substantial progress has been made by explicitly comparing cases of each disorder or 5 subtype. However, given the limitations of our design, further work is needed to consolidate this hypothesis.
Although the gene-by-tissue associations identified point to biologically plausible tissues, we caution against over-interpretation of tissue sources in our study. The power of each tissue-10 specific predictor model (i.e., the accuracy of GReX prediction) is driven partially by the sample size of the expression quantitative trait loci (eQTL) reference panel and gene expression heritability in that tissue (Veturi and Ritchie, 2018) . Additionally, there is a significant amount of eQTL sharing between similar tissues (e.g., within brain) (GTEx Consortium, 2017) . It is also true that these predictor models are derived from bulk tissue and thus, tissue-specific weighs of 15 SNPs might be driven by variations in cell type proportions between tissue-types or other tissuespecific factors. Importantly, using blood gene expression obtained by MRS (Breen et al., 2015) , we observed concordance of predicted PTSD differences and observed PTSD differences with strong evidence for tissue-specificity (i.e. compared to the other tissues, our blood predictions matched better the observed blood differences). 20 Unlike traditional gene expression studies, TI approaches study only GReX. Any case-control differences identified are therefore due only to difference in allele frequencies, rather than influenced by environmental and/or epigenetic factors. These differences therefore cannot stem from differential exposure to trauma, or to any other environmental factors, or factors related to 25 disease state -for example, from manifestation of symptoms or psychiatric medications. As TI models are derived from post-mortem adult tissues, the genotype-gene expression relationships encoded by these models will be biased by unknown stressors and other environmental factors in the lives of donors. As far as possible, we and others have controlled for these factors, including for example, correction for known diagnoses, age, post-mortem interval, smoking status, and 30 surrogate variables (Gamazon et al.; Huckins et al., 2017) , when constructing TI models.
Although these methods may incompletely control for certain stressors, this will not lead to a systematic bias between cases and controls in our study, and as such should not lead to any inflation in our results.
Finally, we find significant evidence for downregulation of SNRNP35 following deployment 5 stress, primarily in PTSD cases. Thus, SNRNP35 downregulation in not only associated with PTSD genetic susceptibility, but also with deployment stress, warranting further exploration. We first knocked-down SNRNP35 gene expression in a cell-culture system to demonstrate that downregulation of this specific subunit of the minor spliceosome is sufficient to cause functional changes in the levels of U12 splicing. Since U12 splicing is not wide-spread in the genome 10 (Turunen et al., 2013) , SNRNP35 downregulation is expected to have a finite number of directly affected downstream pathways that need to be tracked in post-mortem brains from traumaexposed subjects with or without PTSD.
We further confirmed that the administration of high dose of a synthetic stress hormone, 15 mimicking the glucocorticoid elevations after activation of the HPA-axis, can downregulate this gene in the mouse PFC. We used DEX, a potent GR agonist, and the observed Snrnp35 downregulation is likely mediated though GR-binding at specific GBS of the gene. Previous studies have shown that DEX-administration, only at the high dose we used, can increase anxiety in the elevated-plus-maze, and that this elevation can be blocked by an opioid agonist (Vafaei et 20 al., 2008) or can potentiate the hypermotility caused by opioids (Capasso et al., 1992) . These observations open new avenues for future translational studies.
In conclusion, our analyses of GReX in PTSD identified novel genes for PTSD-risk, with a tissue resolution specific to military vs. civilian trauma. We identify SNRNP35 as the most 25 promising gene for further functional investigation of its trauma type specific role in vulnerability to and resilience against PTSD.
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Figure 1. Gene-by-tissue associations with PTSD. (A)
No associations reach study-wide significance (depicted by red discontinuous line) in our overall transethnic meta-analysis, but two genes reach within-tissue significance (depicted by purple discontinuous line). (B) Two genes reach study-wide significance in the military-only meta-analysis and one reached within tissue significance; (C) while no genes are significant at any of the significance thresholds in the civilian-only meta-analysis. Gene-tissue pairs are color-coded according to tissue type.
Figure 2. PTSD genetically-regulated expression (GReX) differences are concordant with the observed blood PTSD gene expression differences in the Marine Resiliency Study.
Correlation between PTSD (vs. controls) fold changes (FC) of observed peripheral leukocyte gene expression in x-axis, measured at pre-(A) and post-deployment (B), and whole blood genetically-regulated expression (GReX) in y-axis. Correspondence between the coefficients of correlation between peripheral leukocyte gene expression and GReX across multiple tissues (xaxis) and level of correspondent significance (y-axis) at pre-(C) and post-deployment (D). Volcano-plot of the post-vs. pre-deployment differential expression changes in subjects with (E) and without (F) post-deployment PTSD. Points in panels C and D are color-coded according to tissue type. Red dots in panel E and F depict significantly upregulated at FDR significance threshold, while the blue depict significantly downregulated at FDR significance threshold. 
METHODS
Genotype data
Genotype data was obtained through the PTSD Workgroup of the Psychiatric Genomics Consortium (PGC-PTSD) data; https://pgc-ptsd.com/). Details regarding participants, genotyping, quality control, imputation, and ancestry assignment were reported previously (Duncan et al.) . PGC-PTSD data used in 5 this manuscript included 32,898 individuals (9,087 cases and 23,811 controls), partitioned according to self-defined ethnicity (broadly, in order of cohort size, European/European-American; African-American;
Hispanic-American/Latin-American; South-African), and trauma type (military/civilian). Due to restrictions on sharing of raw data for some of these cohorts, our study includes analyses of both raw data, and summary statistics ( (Koen et al., 2014; Stein et al., 2015) -Ancestry-specific summary statistics data were available from seven military cohorts prepared with a pipeline described in (Duncan et al., 2018) . The total was 19,959 individuals ( Assess Risk and Resilience in Servicemembers (STARRS) (Stein et al., 2016) ; Pre/Post Deployment Study (PPDS) within Army STARRS (Stein et al., 2016) .
For sex-specific analysis of the same civilian and military cohorts, we also had access to sex-25 specific summary statistics prepared with a pipeline described in (Nievergelt et al., 2018b) . The breakdown of the sex-specific sample sizes can be found in Table S1B .
Transcriptomic Imputation (TI)
We predicted genetically regulated gene expression (GReX) using publicly available predictor models 30 derived from Genotype-Tissue Expression (GTEx) project (v6 release) and CommonMind Consortium (CMC) (v1 release) eQTL reference panels (Gamazon et al., 2015; Huckins et al., 2017) . Briefly, predictor models were created from large, matched collections of genotype and gene expression data.
Elastic net regression was used to identify SNPs within the cis-region (1Mb) that jointly predict the expression of a given gene. For each gene, dosages of SNPs included in the predictor model are weighted and combined to produce an estimate of genetically regulated gene expression. These predictor models may then be applied to genotype data, for example from GWAS studies.
For the PGC-PTSD cohorts for which we had access to raw data, we imputed genetically regulated gene 5 expression (GReX) for each individual, across 11 brain regions, 5 cardiovascular tissues, 2 endocrine tissues, 1 peripheral nerve, 1 adipose tissue and whole blood, driven by prior hypotheses about the involvement of those tissues in PTSD (Averill et al., 2017; Daskalakis et al., 2018a; Nemeroff et al., 2006; Sareen, 2014) using PrediXcan (Gamazon et al., 2015) . We then calculated associations between GReX and case-control status, correcting for ten genotype derived principal-components. For the PGC-10 PTSD, cohorts for which we only had access to summary statistics, we used S-PrediXcan (Barbeira et al., 2018) . In this algorithm, summary statistics for SNPs within each gene model are combined, using model weights and LD between variants, to obtain genic association statistics. We have previously shown that the statistical calculations underlying PrediXcan (raw genotype) and S-PrediXcan (summary statistic based) are analogous (Barbeira et al., 2018; Huckins et al., 2017) . Results from S-PrediXcan and 15
PrediXcan are highly correlated (r≈.99) when applied to European populations, and high (r≈.92) in African American populations (Barbeira et al., 2018) . Since we do not have any validation data for HA/LA ethnicities, and these military cohorts are relatively small (333 cases and 1,690 controls), we did not include genes reaching significance only in the HA/LA cohorts in our results.
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Meta-Analysis
We performed meta-analyses using an inverse variance based approach in METAL (Willer et al., 2010) , for analyses (1) delineated by trauma type (Military/Civilian); and (2) delineated by ancestry. We note that, in this analysis, results from S-prediXcan are scaled to unit variance of a gene, whereas PrediXcan results are not. Therefore, an approach which combines PrediXcan and S-PrediXcan using inverse 25 variance is inappropriate. For the 'overall' analysis we therefore combined cohorts using a sample sizebased approach in METAL. We calculated "effective sample size", N eff , according to the following formula (Willer et al., 2010) : N eff =4/(1/N cases +1/N controls ). Figure S1 illustrates our meta-analysis strategy.
We required that each meta-analysis included at least 1,000 cases. We applied two multiple-test 30 corrections to ascertain significance, following previous PrediXcan literature ( Barbeira et al., 2018; Huckins et al., 2017) . First, a study-wide threshold, using a Bonferroni correction for all genes and tissues tested (p=2.36x10 -7 ; based on 211,466 tissue-gene pairs, across all tissues). Second, a within-tissue significance threshold, accounting for all genes tested in each tissue (Table S2 ). It is likely that the study-wide threshold is overly conservative, given the high degree of eQTL sharing and gene expression correlation between genes and across tissues. Consequently, it is likely that we are performing far fewer independent tests than assumed under a Bonferroni correction. However, applying a less stringent threshold would risk identification of many false positive results, which we are careful to avoid.
MRS validation of whole-blood results
The MRS gene expression data acquisition: Peripheral blood sample acquisition has been described in detail elsewhere (Breen et al., 2015; Glatt et al., 2013; Tylee et al., 2015) . In brief, peripheral blood was 30 obtained from U.S. Marine participants who served a seven-month deployment. Blood was drawn 1month prior to deployment and again at 3-months post-deployment for each participant. Each blood sample (10ml) was collected into an EDTA-coated collection tube, RNA was isolated from peripheral blood leukocytes using LeukoLOCK Total RNA isolation and sequenced using the Illumina Hi-Seq 2000.
From these samples, two separate data sets generated. The first data set of data included a total of 24 paired pre-deployment samples and 24 post-deployment samples, which were subjected to the Affymetrix Hu-Gene 1.0 ST Array. The second data set of data included a total of 130 pre-deployment samples and 134 post-deployment samples which were subjected to RNA-sequencing.
5
MRS gene expression data pre-processing: Data from each data set were processed, normalized and quality treated independently. Affymetrix arrays underwent robust multi-array average (RMA) normalization with additional GC-correction when possible [affy, oligo, gcrma (Wu et al., 2012) ]. When multiple microarray probes mapped to the same HGNC symbol, the probes with the highest average expression across all samples was selected. RNA-sequencing were mapped and counted as described 10 previously 1 . Genes with with >2 count per million (cpm) in at least 50% of all samples were retained and subsequently normalized using VOOM in limma (Ritchie et al., 2015) , a variance-stabilization transformation method resulting in a normally distributed data matrix. For each data set, normalized data were inspected for outlying samples using unsupervised hierarchical clustering of samples (based on
Pearson's coefficient and average distance metric) and principal component analysis to identify potential 15 outliers outside two standard deviations from these grand averages; ten outliers were removed in total. A total of 11,090 genes were expressed in both microarray and RNA-sequencing data sets, for which 6,295 genes (56.7%) also had predicted GReX expression. Combat batch correction (Leek et al., 2012) was applied to combine the two datasets and reduce systematic sources of variability other than case/control status, such as technical variability, forming the bases for subsequent case-control analytic comparisons.
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MRS differential gene expression (DGE): DGE analysis was performed using the limma package (Ritchie et al., 2015) to detect relationships between diagnostic status and gene expression levels. The covariates ancestry (genetic PC1), age, traumatic brain injury (TBI), alcohol and nicotine were included in all models to adjust for their potential confounding influence on gene expression between main group 25 effects.
Gene-set enrichment tests
We performed gene-set enrichment tests using MAGMA (de Leeuw et al., 2015) . We created a set of associations statistics using results from the overall, C-PTSD, and M-PTSD transethnic meta-analyses.
30
For each set of results, we selected the best (most significant) P-value per gene, applying a Bonferroni correction to account for the number of tissues tested. We performed three gene-set enrichment analyses for each of our association statistics.
First, we tested for enrichment of genes from PTSD literature. We downloaded from PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) the 700+ publication list according to "PTSD" & "gene" search (November 1, 2017) . From these publications, we discarded the ones that were not original investigations.
From the remaining 511 publications (Table S5) , we were able to extract 143 unique gene symbols from the publication title irrespective if the reported findings were positive or negative. The most frequent 5 being the serotonin transporter gene (SLC6A4 in 35 publications). Of these 143 genes, 103 were included in our transcriptomic imputation analyses. Second, we tested for enrichment of 92 hypothesis-driven pathways, including gene-sets associated with other psychiatric disorders, stress hormones, and genes with H3K4me3 or H3K27ac peaks in neurons, or non-neurons (Girdhar et al., 2018 ). Third, we tested 8,582 gene-sets collated from publicly available databases including KEGG, GO, REACTOME, 10 PANTHER, BIOCARTA, and MGI. For all gene-set analyses, we included only gene-sets with at least ten genes and used the "competitive" P-value from MAGMA. We applied an FDR-correction within each experiment to correct for multiple testing. 
Δ Δ
Ct method unless otherwise stated. Primer combinations are given in Table S14 . 
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Figure S2.
Analytical approach for quality control, batch correction, and differential gene expression in the Marine Resiliency Study. Figure S3 . The area of the PFC mouse punch. Cg1: cingulate cortex, area 1; PrL: prelimbic cortex; IL: infralimbic cortex; DP: dorsal peduncular cortex.
